<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>What's new in oncology</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">What's new in oncology</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">What's new in oncology</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 01, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p>The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.</p><p class="headingAnchor" id="H164_142566"><span class="h1">BREAST CANCER</span></p><p class="headingAnchor" id="H143971"><span class="h2">Improvement in breast cancer mortality from 1975 to 2019 (January 2024)</span></p><p>Improvements in breast cancer screening and treatments are decreasing breast cancer mortality. In a study using four simulation models of breast cancer mortality rates in the United States (US), breast cancer screening and treatment in 2019 were associated with a 58 percent reduction in US breast cancer mortality compared with 1975 [<a href="#rid1">1</a>]. Approximately half of this reduction was due to treatment of early breast cancer, while the rest was divided roughly equally between treatment of metastatic breast cancer and breast cancer screening. We support breast cancer screening for appropriate candidates and incorporate novel, data-driven strategies into our treatment recommendations for breast cancer. (See  <a class="medical medical_review" href="/d/html/737.html" rel="external">"Overview of the treatment of newly diagnosed, invasive, non-metastatic breast cancer", section on 'Introduction'</a> and  <a class="medical medical_review" href="/d/html/7564.html" rel="external">"Screening for breast cancer: Strategies and recommendations"</a>.)</p><p class="headingAnchor" id="H142446"><span class="h2">Omission of radiation in select patients with favorable-risk breast cancer (August 2023, Modified January 2024)</span></p><p>Trials are examining omission of radiation in early, favorable-risk breast cancer. </p><p class="bulletIndent1"><span class="glyph">●</span>In a single-arm trial including 500 females ≥55 years with T1N0, grade 1 or 2, luminal A-breast cancer, breast-conserving surgery and endocrine therapy without radiation were associated with a low incidence of local recurrence at five years (2.3 percent) [<a href="#rid2">2</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>A prospective study found that patients ≥50 years with nontriple negative cT1N0 breast cancer that was unifocal on preoperative MRI and pT1N0 or N1mi at the time of surgery could omit adjuvant radiation and experience a low ipsilateral invasive recurrence rate (1 percent at five years) [<a href="#rid3">3</a>].</p><p>We consider omission of adjuvant radiation to be an option in women ≥65 years with clinically node-negative, small (tumor size &lt;3 cm), hormone receptor-positive, HER2-negative breast cancer who are willing to take adjuvant endocrine therapy, but we await further data before omitting radiation in other patients. (See  <a class="medical medical_review" href="/d/html/739.html" rel="external">"Adjuvant radiation therapy for women with newly diagnosed, non-metastatic breast cancer", section on 'Possible omission of RT for select ER-positive, HER2-negative cancers'</a>.)</p><p class="headingAnchor" id="H143422"><span class="h2">Regional nodal radiation in early breast cancer (November 2023)</span></p><p>Studies are evaluating the impact of adjuvant regional nodal radiotherapy (RT) in patients with early breast cancer. In a meta-analysis including over 12,000 patients, absolute improvements in breast cancer recurrence and mortality from regional nodal RT in trials from the 1990s through 2000s were greatest for patients at highest risk for recurrence; absolute reductions in 15-year breast cancer mortality were 1 to 2 percent among those with no positive axillary lymph nodes, 2 to 3 percent among those with one to three positive nodes, and 4 to 5 percent for those with four or more positive nodes [<a href="#rid4">4</a>]. However, no benefits were observed in earlier trials of nodal RT. The discrepancy is likely due to refinements in radiation techniques. For patients with node-positive or high-risk node-negative breast cancer, we offer adjuvant regional nodal RT. (See  <a class="medical medical_review" href="/d/html/739.html" rel="external">"Adjuvant radiation therapy for women with newly diagnosed, non-metastatic breast cancer", section on 'Approach'</a>.)</p><p class="headingAnchor" id="H142667"><span class="h2">Peritumoral lidocaine injection before incision for breast cancer surgery (September 2023)</span></p><p>In a multicenter, randomized trial of over 1000 patients with early breast cancer undergoing mastectomy or breast-conserving surgery, peritumoral injection of 0.5% <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> prior to incision improved five-year disease-free survival (87 versus 83 percent) and five-year overall survival (90 versus 86 percent) [<a href="#rid5">5</a>]. The mechanism is unknown but thought to involve blocking voltage-gated sodium channels and thereby preventing activation of prometastatic pathways. The trial protocol for surgical management of breast cancer deviated from what may be considered standard treatment in many clinical practices, so further validation is necessary; however, peritumoral injection of lidocaine may be a reasonable intervention given its simplicity and minimal cost. (See  <a class="medical medical_review" href="/d/html/807.html" rel="external">"Breast-conserving therapy", section on 'Incision'</a>.)</p><p class="headingAnchor" id="H142566"><span class="h2">Sacituzumab govitecan in hormone receptor-positive, HER2-negative metastatic breast cancer (August 2023)</span></p><p><a class="drug drug_general" data-topicid="127999" href="/d/drug information/127999.html" rel="external">Sacituzumab govitecan</a> (SG) is an antibody-drug conjugate that previously showed progression-free survival benefits over clinician's choice of therapy in patients with metastatic, heavily pretreated, hormone receptor (HR)-positive, HER2-negative breast cancer; overall survival results from that randomized trial are now available. Among 543 patients, the overall survival with SG was 14.4 versus 11.2 months with clinician's choice of therapy [<a href="#rid6">6</a>]. SG has regulatory approval in the United States for patients with unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting [<a href="#rid7">7,8</a>]. (See  <a class="medical medical_review" href="/d/html/83848.html" rel="external">"Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer", section on 'Sacituzumab govitecan'</a>.)</p><p class="headingAnchor" id="H142357"><span class="h2">Pretreatment staging of locally advanced breast cancer (August 2023)</span></p><p>For patients with locally advanced breast cancer, pretreatment imaging is typically obtained to rule out metastatic disease, but the optimal modality is under investigation. In a randomized trial in 369 patients with stage III or IIb (T3N0, but not T2N1) breast cancer, 23 percent of patients assigned to staging with positron emission tomography-computed tomography (PET-CT) were upstaged to stage IV compared with 11 percent assigned to CT of the chest, abdomen, and pelvis (CT C/A/P) and bone scan [<a href="#rid9">9</a>]. This resulted in changes in treatment strategy, such that fewer patients in the PET-CT group received combined modality therapy (81 versus 89 percent). For patients with stage IIIA or higher disease, regardless of whether symptoms are present, we obtain a whole-body PET-CT for staging, but we consider a bone scan plus CT C/A/P to be a reasonable alternative. (See  <a class="medical medical_review" href="/d/html/744.html" rel="external">"Clinical features, diagnosis, and staging of newly diagnosed breast cancer", section on 'Role of imaging'</a>.)</p><p class="headingAnchor" id="H166_143149"><span class="h1">ENDOCRINE TUMORS</span></p><p class="headingAnchor" id="H143149"><span class="h2">Selpercatinib for RET-mutated medullary thyroid cancer (November 2023)</span></p><p>In an open-label, randomized trial comparing <a class="drug drug_general" data-topicid="128157" href="/d/drug information/128157.html" rel="external">selpercatinib</a> (a selective RET inhibitor) with either <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> or <a class="drug drug_general" data-topicid="16484" href="/d/drug information/16484.html" rel="external">vandetanib</a> (less selective antiangiogenic kinase inhibitors with some RET inhibition) in 291 patients with progressive, locally advanced or metastatic <em>RET-</em>mutated medullary thyroid cancer, median progression-free survival was not reached in the selpercatinib group and was 16.8 months in the active comparator group [<a href="#rid10">10</a>]. The 12-month progression-free survival was better with selpercatinib (87 versus 66 percent with cabozantinib or vandetanib); complete response occurred in 12 and 4 percent, respectively. There were fewer grade ≥3 adverse events in the selpercatinib group, and fewer patients discontinued treatment due to adverse events. These finding support our recommendation for selpercatinib as initial therapy in patients with <em>RET</em>-mutated tumors who meet criteria for systemic treatment. (See  <a class="medical medical_review" href="/d/html/2188.html" rel="external">"Medullary thyroid cancer: Systemic therapy and immunotherapy", section on 'Selpercatinib'</a>.)</p><p class="headingAnchor" id="H167_142715"><span class="h1">GASTROINTESTINAL CANCER</span></p><p class="headingAnchor" id="H143131"><span class="h2">Model for End-stage Liver Disease (MELD) 3.0 for liver transplantation (October 2023, Modified December 2023)</span></p><p>The Model for End-stage Liver Disease (MELD) score is used to allocate livers for transplantation. Recently, the Organ Procurement and Transplantation Network implemented an updated score, MELD 3.0, for prioritizing liver transplantation candidates who are ages 12 and older [<a href="#rid11">11</a>]. MELD 3.0 includes variables from the original model (ie, serum bilirubin, serum creatinine, and international normalized ratio) in addition to other inputs (ie, serum sodium, patient sex, and serum albumin) and a lower creatinine ceiling. Goals of using MELD 3.0 include reducing overall waitlist mortality and improving access for female liver transplant candidates. (See  <a class="medical medical_review" href="/d/html/1241.html" rel="external">"Model for End-stage Liver Disease (MELD)", section on 'MELD 3.0'</a>. and  <a class="medical medical_review" href="/d/html/2490.html" rel="external">"Liver transplantation for hepatocellular carcinoma", section on 'MELD 3.0'</a>.)</p><p class="headingAnchor" id="H143156"><span class="h2">Risk of pancreatic cancer in stable intraductal papillary mucinous neoplasms (November 2023)</span></p><p>The optimal duration of pancreatic cancer surveillance in patients with branch duct intraductal papillary mucinous neoplasms (BD-IPMNs) is unclear. In a study of over 3800 such patients without worrisome features (WFs) or high-risk stigmata (HRS), 42 percent had BD-IPMNs that remained stable in size and did not develop WF/HRS for at least five years [<a href="#rid12">12</a>]. Within this group, patients ≥75 years with cysts &lt;30 mm and those ≥65 years with cysts &lt;15 mm had a standardized incidence ratio for pancreatic cancer comparable to the general population and low disease-specific mortality. These data suggest that this subgroup may be able to discontinue pancreatic cancer surveillance; however, further studies are needed to validate these results. (See  <a class="medical medical_review" href="/d/html/5632.html" rel="external">"Intraductal papillary mucinous neoplasm of the pancreas (IPMN): Pathophysiology and clinical manifestations", section on 'Pancreatic malignancy'</a>.)</p><p class="headingAnchor" id="H143141"><span class="h2">Sotorasib plus panitumumab for KRAS G12C mutant metastatic colorectal cancer (November 2023)</span></p><p>For patients with treatment-refractory, <em>KRAS </em>G12C mutant metastatic colorectal cancer (mCRC), studies are evaluating <a class="drug drug_general" data-topicid="131755" href="/d/drug information/131755.html" rel="external">sotorasib</a>, an irreversible inhibitor of KRAS G12C. In a phase III trial in 160 patients with treatment-refractory <em>KRAS </em>G12C mutant mCRC, sotorasib 960 mg daily plus <a class="drug drug_general" data-topicid="10336" href="/d/drug information/10336.html" rel="external">panitumumab</a> improved progression-free survival (median 5.6 versus 2.2 months) compared with <a class="drug drug_general" data-topicid="104185" href="/d/drug information/104185.html" rel="external">trifluridine-tipiracil</a> or <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a> at median follow-up of eight months and was well tolerated [<a href="#rid13">13</a>]. For patients with KRAS G12C mutant mCRC who progress on multiple agents including chemotherapy and vascular endothelial growth factor inhibitors, we consider sotorasib plus panitumumab to an acceptable treatment option. (See  <a class="medical medical_review" href="/d/html/129349.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'RAS-mutated tumors'</a>.)</p><p class="headingAnchor" id="H143337"><span class="h2">Gemcitabine plus cisplatin and pembrolizumab for advanced cholangiocarcinoma (November 2023)</span></p><p>Advanced cholangiocarcinoma is an aggressive disease with poor survival outcomes, so there is interest in investigating novel approaches, such as the addition of immunotherapy to chemotherapy. In a placebo-controlled, phase III trial of over 1000 patients with treatment-naïve, locally advanced or metastatic biliary tract cancers, the addition of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> to <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> improved overall survival (median 13 versus 11 months) with an acceptable toxicity profile [<a href="#rid14">14</a>]. Based on these data, pembrolizumab, in combination with gemcitabine plus cisplatin, was approved by the US Food and Drug Administration for the treatment of locally advanced unresectable or metastatic biliary tract cancer [<a href="#rid15">15</a>]. We consider this combination to be an appropriate initial treatment option in fit patients with advanced or metastatic cholangiocarcinoma and no hyperbilirubinemia. (See  <a class="medical medical_review" href="/d/html/2524.html" rel="external">"Systemic therapy for advanced cholangiocarcinoma", section on 'Gemcitabine plus cisplatin and pembrolizumab'</a>.)</p><p class="headingAnchor" id="H143092"><span class="h2">Trastuzumab plus tucatinib for advanced cholangiocarcinoma (November 2023)</span></p><p>For patients with advanced or metastatic human epidermal growth factor 2 (HER2)-positive cholangiocarcinoma who progress on chemotherapy, studies are evaluating <a class="drug drug_general" data-topicid="127946" href="/d/drug information/127946.html" rel="external">tucatinib</a>, an oral, highly selective HER2 inhibitor. In a phase II trial in 30 patients with previously treated HER2-positive cholangiocarcinoma, <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> plus tucatinib was associated with an objective response rate of 47 percent [<a href="#rid16">16</a>]. For patients with advanced or metastatic HER2-positive cholangiocarcinoma who progress on <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>, platinum, and/or fluorouracil-based chemotherapy, trastuzumab plus tucatinib is an acceptable option for later-line therapy. (See  <a class="medical medical_review" href="/d/html/2524.html" rel="external">"Systemic therapy for advanced cholangiocarcinoma", section on 'HER2-positive tumors'</a>.)</p><p class="headingAnchor" id="H142814"><span class="h2">Selecting radiation therapy for total neoadjuvant therapy in locally advanced rectal cancer (October 2023)</span></p><p>For patients with locally advanced rectal cancer (LARC) who are treated with total neoadjuvant therapy (TNT; neoadjuvant chemotherapy and radiation therapy [RT] prior to surgical evaluation), the optimal RT schedule is not established. In extended follow-up of a randomized trial in over 900 patients with LARC, TNT using short-course RT (25 Gray total over 5 fractions) had worse five-year locoregional recurrence rates (10 versus 6 percent) and similar overall survival (82 versus 81 percent) relative to neoadjuvant long-course chemoradiation (CRT; 50.4 to 54 Gray total over 28 to 31 fractions, followed by surgery and adjuvant chemotherapy) [<a href="#rid17">17</a>]. Based on these data, for most patients with LARC selecting between RT schedules for TNT, we suggest long-course CRT rather than short-course RT. (See  <a class="medical medical_review" href="/d/html/2468.html" rel="external">"Neoadjuvant therapy for rectal adenocarcinoma", section on 'Selection of RT schedule'</a>.)</p><p class="headingAnchor" id="H142408"><span class="h2">Sugar-sweetened beverages and risk of liver cancer (September 2023)</span></p><p>There is interest in evaluating the impact of sugar-sweetened beverages (such as regular sodas and fruit drinks) on the risk of developing liver cancer. In an observational study of almost 99,000 postmenopausal females, higher intake of sugar-sweetened beverages (one or more servings per day) was associated with an increased risk of developing liver cancer (hazard ratio 1.85) relative to less frequent consumption (three or less servings per month) [<a href="#rid18">18</a>]. These findings support the importance of limiting or avoiding sugar-sweetened beverages as part of a healthy diet for adults and for cancer prevention. (See  <a class="medical medical_review" href="/d/html/3599.html" rel="external">"Epidemiology and risk factors for hepatocellular carcinoma", section on 'Dietary factors'</a>.)</p><p class="headingAnchor" id="H142715"><span class="h2">FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with isolated liver metastases (September 2023)</span></p><p>In patients with metastatic colorectal cancer (mCRC) and isolated hepatic metastases, studies are investigating the optimal approach to systemic therapy. In a phase III trial in almost 300 patients with unresectable mCRC limited to the liver and a right-sided <em>RAS/BRAF</em> V600E mutant primary tumor, initial therapy with FOLFOXIRI (infusional <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> [FU], <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> [LV], <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>, and <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>) plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> for up to six months improved progression-free survival relative to FOLFOX (oxaliplatin plus LV and short-term infusional FU) or FOLFIRI (irinotecan plus LV and short-term infusional FU) plus bevacizumab (11 versus 9 months) [<a href="#rid19">19</a>]. Rates of complete local treatment (with either surgery or radiation) of hepatic metastases were also higher (51 versus 37 percent). For patients with <em>RAS/BRAF</em> V600E mutant mCRC and initially unresectable isolated liver disease, we suggest initial systemic therapy with FOLFOXIRI plus bevacizumab. (See  <a class="medical medical_review" href="/d/html/2483.html" rel="external">"Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'RAS/BRAF mutant disease'</a>.)</p><p class="headingAnchor" id="H142533"><span class="h2">Divarasib in G12C KRAS-mutant solid tumors (September 2023)</span></p><p>Novel agents are under investigation for G12C <em>KRAS</em>-mutant solid tumors. In a phase I study in 137 patients with advanced <em>KRAS</em>-mutant cancers, among the 60 patients with non-small cell lung cancer, the objective response rate to the covalent <em>KRAS </em>G12C inhibitor divarasib was 53 percent, with a median progression-free survival (PFS) of 13.1 months; among the subgroup of 55 patients with metastatic colorectal cancer, the response rate was 29 percent, with a median PFS of 6 months [<a href="#rid20">20</a>]. Responses were also observed in patients with other solid tumors. Treatment was generally well tolerated, with grade ≥3 events occurring in 12 percent of patients. We await further data and/or regulatory approval prior to use of divarasib in G12C <em>KRAS</em>-mutant solid tumors. (See  <a class="medical medical_review" href="/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer", section on 'Others'</a> and  <a class="medical medical_review" href="/d/html/129349.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'RAS-mutated tumors'</a>.)</p><p class="headingAnchor" id="H168_142495"><span class="h1">GENITOURINARY ONCOLOGY</span></p><p class="headingAnchor" id="H143280"><span class="h2">Novel treatment approaches for metastatic urothelial carcinoma (December 2023)</span></p><p>For patients with metastatic urothelial carcinoma (UC), randomized trials are evaluating treatments that improve upon the efficacy and/or tolerability of platinum-based chemotherapy:</p><p class="bulletIndent1"><span class="glyph">●</span>Among 900 patients with previously untreated locally advanced or metastatic UC eligible for platinum-based chemotherapy, <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> (an antibody-drug conjugate) plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> improved overall survival (median 31 versus 16 months) versus platinum-based chemotherapy with less grade ≥3 toxicity (56 versus 70 percent) [<a href="#rid21">21</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>Among 600 cisplatin-eligible patients with advanced or metastatic UC, the addition of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> to <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> improved overall survival (median 22 versus 19 months) [<a href="#rid22">22</a>]. </p><p>Based on these data, for patients with metastatic UC, we now offer initial treatment with <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> but consider <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> to be a reasonable alternative. (See  <a class="medical medical_review" href="/d/html/3000.html" rel="external">"Treatment of metastatic urothelial carcinoma of the bladder and urinary tract", section on 'Enfortumab vedotin plus pembrolizumab'</a> and  <a class="medical medical_review" href="/d/html/3000.html" rel="external">"Treatment of metastatic urothelial carcinoma of the bladder and urinary tract", section on 'Nivolumab plus gemcitabine plus cisplatin'</a>.)</p><p class="headingAnchor" id="H143359"><span class="h2">Enzalutamide and androgen deprivation therapy in prostate cancer with high-risk biochemical recurrence (November 2023)</span></p><p>Trials are evaluating novel hormonal agents such as <a class="drug drug_general" data-topicid="86370" href="/d/drug information/86370.html" rel="external">enzalutamide</a> in subsets of males with recurrent prostate cancer. In a randomized trial in over 1000 males with high-risk biochemical recurrence, enzalutamide plus androgen deprivation therapy (ADT) improved five-year metastasis-free survival compared with enzalutamide alone (87 versus 80 percent) or ADT alone (87 versus 71 percent) [<a href="#rid23">23</a>]. The five-year overall survival in the combination group was improved compared with ADT alone (92 versus 87 percent). Treatment was discontinued due to adverse events in 21 percent of patients in the combination group, 18 percent in the enzalutamide-alone group, and 10 percent in the leuprolide-alone group. Based on these results, we suggest enzalutamide and ADT as initial treatment for prostate cancer with high-risk biochemical recurrence. (See  <a class="medical medical_review" href="/d/html/6933.html" rel="external">"Role of systemic therapy in patients with a biochemical recurrence after treatment for localized prostate cancer", section on 'Second generation nonsteroidal antiandrogens plus ADT'</a>.)</p><p class="headingAnchor" id="H142836"><span class="h2">Lenvatinib plus pembrolizumab for advanced non-clear cell renal carcinoma (October 2023)</span></p><p>Advanced non-clear cell renal cell carcinoma (RCC) is rare, and there are limited data on the optimal approach to initial therapy. In a phase II trial in over 150 patients with advanced, systemic, therapy-naïve non-clear cell RCC, objective responses for <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> by histology were 67 percent for those with translocation RCC, 54 percent for those with papillary RCC, 52 percent for those with unclassified RCC, and 28 percent for those with chromophobe RCC [<a href="#rid24">24</a>]. We suggest lenvatinib plus pembrolizumab as initial therapy for patients with translocation RCC, and we consider this combination as one of several appropriate initial options for the other histologies. (See  <a class="medical medical_review" href="/d/html/96030.html" rel="external">"The treatment of advanced non-clear cell renal carcinoma", section on 'Lenvatinib plus pembrolizumab'</a>.)</p><p class="headingAnchor" id="H142495"><span class="h2">Standard versus extended lymphadenectomy for radical cystectomy (August 2023)</span></p><p>The benefit of an extended lymphadenectomy during radical cystectomy is controversial. In a phase III trial, 618 patients with cT2-4a N0-2 bladder cancer underwent radical cystectomy with standard or extended lymphadenectomy and were followed for six years [<a href="#rid25">25</a>]. Although more lymph nodes were removed with extended lymphadenectomy (median 39 versus 25), this did not result in more favorable outcomes as rates of nodal metastasis, disease-free survival, and overall survival were similar. Furthermore, extended lymphadenectomy resulted in a higher rate of severe complications (16 versus 8 percent) and more deaths within 90 days (19 versus 7 patients). Given these results, radical cystectomy should be performed with bilateral standard lymphadenectomy, which includes removal of at least 12 external and internal iliac and obturator nodes. (See  <a class="medical medical_review" href="/d/html/2974.html" rel="external">"Radical cystectomy", section on 'Lymphadenectomy'</a>.)</p><p class="headingAnchor" id="H143806"><span class="h2">Belzutifan for advanced clear cell renal carcinoma (January 2023)</span></p><p>For patients with advanced clear cell renal carcinoma (RCC), studies are evaluating targeted agents such as <a class="drug drug_general" data-topicid="132401" href="/d/drug information/132401.html" rel="external">belzutifan</a>, a small molecule inhibitor of hypoxia-inducible factor 2 alpha (HIF-2a). In a randomized trial in approximately 750 patients with treatment-refractory advanced or metastatic clear cell RCC, belzutifan improved progression-free survival (PFS) over <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> (18-month PFS 23 versus 9 percent) and was well tolerated [<a href="#rid26">26</a>]. Based on these data, the US Food and Drug Administration approved belzutifan for patients with advanced RCC following treatment with an immune checkpoint inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor. (See  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma", section on 'Belzutifan'</a>.)</p><p class="headingAnchor" id="H169_142820"><span class="h1">GYNECOLOGIC ONCOLOGY</span></p><p class="headingAnchor" id="H143869"><span class="h2">Atezolizumab in metastatic cervical cancer (January 2024)</span></p><p>Trials are evaluating the addition of immunotherapy to chemotherapy as initial systemic treatment for metastatic cervical cancer. In an open-label randomized trial in 410 patients with metastatic or recurrent cervical cancer not amenable to curative treatment, the addition of the checkpoint inhibitor <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> to chemotherapy and <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> improved both median progression-free survival (13.7 versus 10.4 months) and overall survival (32 versus 23 months) [<a href="#rid27">27</a>]. Grade ≥3 events occurred in 79 percent receiving atezolizumab and 75 percent in the control group. Although this approach does not yet have regulatory approval, we consider it to be an appropriate initial treatment in patients with metastatic cervical cancer not amenable to curative treatment. (See  <a class="medical medical_review" href="/d/html/3185.html" rel="external">"Management of recurrent or metastatic cervical cancer", section on 'Atezolizumab'</a>.)</p><p class="headingAnchor" id="H143667"><span class="h2">Mirvetuximab soravtansine in folate receptor alpha-positive ovarian cancer (December 2023)</span></p><p><a class="drug drug_general" data-topicid="140191" href="/d/drug information/140191.html" rel="external">Mirvetuximab soravtansine</a> (MIRV) is a folate receptor (FR) alpha-directed antibody and microtubule inhibitor conjugate that is being evaluated for platinum-resistant, FR alpha-positive epithelial ovarian cancer (EOC). In a randomized trial of MIRV versus investigator's choice chemotherapy in 453 patients with such cancers, MIRV improved objective response rates (42 versus 16 percent), progression-free survival (5.6 versus 4.0 months), and overall survival (16.5 versus 12.8 months) [<a href="#rid28">28</a>]. Grade ≥3 adverse events were less common in the MIRV group (42 versus 54 percent). Based on these results, MIRV has regulatory approval in the United States for FR alpha-positive, platinum-resistant EOC that has been treated with one to three prior systemic treatment regimens. (See  <a class="medical medical_review" href="/d/html/3240.html" rel="external">"Medical treatment for relapsed epithelial ovarian, fallopian tube, or peritoneal cancer: Platinum-resistant disease", section on 'Mirvetuximab soravtansine'</a>.)</p><p class="headingAnchor" id="H142820"><span class="h2">Avoidance of PARP inhibitors as maintenance for platinum-sensitive relapsed ovarian cancer (September 2023)</span></p><p>For advanced epithelial ovarian cancer (EOC) with platinum-sensitive relapse, poly(ADP-ribose) polymerase (PARP) inhibitors were previously an option for maintenance therapy, irrespective of the presence of a <em>BRCA</em> mutation. However, this strategy no longer has regulatory approval in the United States for patients with <em>BRCA </em>wildtype cancers due to a lack of survival benefit in this population [<a href="#rid29">29-31</a>]. For patients with <em>BRCA</em> wildtype cancers and platinum-sensitive relapse, we use <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> with platinum-based chemotherapy rather than a PARP inhibitor and continue as maintenance treatment. (See  <a class="medical medical_review" href="/d/html/16755.html" rel="external">"Medical treatment for relapsed epithelial ovarian, fallopian tube, or peritoneal cancer: Platinum-sensitive disease", section on 'PARP inhibitors no longer used'</a>.)</p><p class="headingAnchor" id="H170_142816"><span class="h1">HEAD AND NECK CANCER</span></p><p class="headingAnchor" id="H142689"><span class="h2">Dysphagia-optimized intensity-modulated radiation therapy (DO-IMRT) in patients with head and neck cancer (October 2023)</span></p><p>Dysphagia-optimized intensity-modulated radiation therapy (DO-IMRT), which reduces the radiation doses to the pharyngeal muscles, is under investigation as a method to decrease treatment-related toxicity in patients with head and neck cancer. In a randomized trial in patients with pharyngeal or hypopharyngeal cancer, DO-IMRT modestly improved swallowing function at 12 months compared with standard IMRT group on a scale of patient-reported outcomes [<a href="#rid32">32</a>]. Additional data, including long-term outcomes, are needed to determine the optimal method of administering IMRT. (See  <a class="medical medical_review" href="/d/html/3406.html" rel="external">"General principles of radiation therapy for head and neck cancer", section on 'Intensity-modulated RT'</a>.)</p><p class="headingAnchor" id="H142816"><span class="h2">Epstein-Barr virus screening strategies for nasopharyngeal carcinoma (September 2023)</span></p><p>Various indicators of Epstein-Barr virus (EBV) infection have been investigated as screening strategies for nasopharyngeal carcinoma (NPC) in endemic areas. In a case-control study in Taiwan, EBV DNA load had both higher sensitivity (93 versus 88 percent) and specificity (98 versus 95 percent) compared with EBV antibodies [<a href="#rid33">33</a>]. A second study used a peptide library of EBV sequences to identify anti-BNLF2b (P85-Ab) as a possible novel serologic biomarker for NPC [<a href="#rid34">34</a>]. In a prospective cohort in almost 25,000 participants in China, including 47 patients with NPC, P85-Ab had better sensitivity and specificity than a standard two-antibody-based screening method. While these results are promising, the optimal screening strategy for NPC is still under investigation. (See  <a class="medical medical_review" href="/d/html/3404.html" rel="external">"Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma", section on 'Screening based on Epstein-Barr virus testing'</a>.)</p><p class="headingAnchor" id="H171_142067"><span class="h1">MELANOMA AND OTHER SKIN CANCER</span></p><p class="headingAnchor" id="H143197"><span class="h2">Tebentafusp and uveal melanoma (November 2023)</span></p><p>In patients with human leukocyte antigen (HLA)-A*02:01-positive metastatic uveal melanoma, a randomized trial previously showed an improvement in overall survival (OS) with <a class="drug drug_general" data-topicid="134894" href="/d/drug information/134894.html" rel="external">tebentafusp</a> compared with clinician's choice of systemic therapy at a median follow-up of 14 months. Now, with longer follow-up of 36 months, improvements in OS persist (three-year OS 27 versus 18 percent; median OS 22 versus 17 months) [<a href="#rid35">35,36</a>]. Improvements were also seen in progression-free survival (median 3.4 versus 2.9 months) and objective response rates (11 versus 5 percent). Adverse events were similar to previous reports. With the longer follow-up of this trial, tebentafusp remains the recommended first-line therapy for patients with HLA-A*02:01-positive metastatic uveal melanoma. (See  <a class="medical medical_review" href="/d/html/113047.html" rel="external">"Metastatic uveal melanoma", section on 'Tebentafusp'</a>.)</p><p class="headingAnchor" id="H142067"><span class="h2">Adjuvant nivolumab in resected Merkel cell carcinoma (July 2023)</span></p><p>Several studies are investigating neoadjuvant and adjuvant therapies in patients with resected Merkel cell carcinoma (MCC). In an open-label, phase II trial, patients with any stage, completely resected MCC were randomly assigned after surgery to one year of adjuvant <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> versus surveillance [<a href="#rid37">37</a>]. The disease-free survival rate at 24 months was 84 percent with nivolumab versus 73 percent with observation only. Overall survival results are immature. We await further data prior to incorporating adjuvant nivolumab for MCC into routine clinical practice. (See  <a class="medical medical_review" href="/d/html/7609.html" rel="external">"Staging, treatment, and surveillance of locoregional Merkel cell carcinoma", section on 'Adjuvant systemic therapy'</a>.)</p><p class="headingAnchor" id="H172_142324"><span class="h1">NEUROONCOLOGY</span></p><p class="headingAnchor" id="H143702"><span class="h2">Intraoperative techniques for glioblastoma resection (December 2023)</span></p><p>Several intraoperative neurosurgical techniques are available to improve the extent of glioblastoma resection while minimizing damage to normal brain, but little comparative data exist. In a multicenter parallel-group trial that included over 300 patients undergoing resection of a newly diagnosed glioblastoma, rates of complete resection were comparable with use of either intraoperative magnetic resonance imaging (iMRI) or 5-aminolevulinic acid (ALA; 81 and 78 percent, respectively) [<a href="#rid38">38</a>]. In both groups, absence of any enhancing tumor postoperatively was associated with improved progression-free and overall survival. These results further support use of adjunctive tools like iMRI and ALA to facilitate maximal safe resection; selection of a specific operative plan is individualized based on neurosurgeon preference, tumor location, and availability of various technologies. (See  <a class="medical medical_review" href="/d/html/5228.html" rel="external">"Clinical presentation, diagnosis, and initial surgical management of high-grade gliomas", section on 'Intraoperative techniques'</a>.)</p><p class="headingAnchor" id="H142823"><span class="h2">BRAF/MEK targeted therapy in pediatric low-grade glioma (September 2023)</span></p><p>Targeted therapy is preferred for many children with<em> BRAF</em> V600E-mutant low-grade gliomas who require treatment beyond surgery. In a randomized, open-label, phase 2 trial in 110 such children requiring treatment after surgery for either symptoms or progression, first-line targeted BRAF/MEK inhibition (<a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a>) improved overall response rate compared with <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> plus <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> chemotherapy (47 versus 11 percent); it also improved median progression-free survival (20.1 versus 7.4 months) and was better tolerated [<a href="#rid39">39</a>]. Overall survival data are not yet mature. Although not compared with radiation therapy, targeted therapy has the advantage of avoiding or at least delaying the long-term neurologic and cognitive consequences of radiation, which are of particular concern in younger patients. (See  <a class="medical medical_review" href="/d/html/5202.html" rel="external">"Uncommon brain tumors", section on 'Ganglioglioma and gangliocytoma'</a>.)</p><p class="headingAnchor" id="H142580"><span class="h2">Prevalence of Lynch syndrome in younger adults with glioblastoma (August 2023)</span></p><p>Mismatch repair (MMR) deficiency and Lynch syndrome are rare among patients with glioma as a whole, but certain patients are at increased risk. In a study that included 1225 adult glioma samples referred to a single neuropathology department, nine gliomas were MMR deficient (0.73 percent), including eight isocitrate dehydrogenase (IDH)-wildtype glioblastomas [<a href="#rid40">40</a>]. In a complementary analysis that included &gt;250 additional IDH-wildtype glioblastomas enriched for young-onset cases, the rate of MMR deficiency was as high as 12.5 percent in patients between 18 and 39 years of age. Based on these data, we suggest tumor testing for MMR deficiency in IDH-wildtype glioblastomas in patients younger than 50 years at diagnosis; all patients with MMR deficiency on somatic (tumor) testing should be offered genetic counseling and germline testing for Lynch syndrome. (See  <a class="medical medical_review" href="/d/html/5214.html" rel="external">"Risk factors for brain tumors", section on 'Mismatch repair deficiency'</a>.)</p><p class="headingAnchor" id="H142324"><span class="h2">Resection versus biopsy of glioblastoma in older adults (August 2023)</span></p><p>The role of surgical resection in older adults with glioblastoma is controversial. In the first completed trial, 101 older adults (≥70 years) with a suspected operable glioblastoma were randomly assigned to either resection or biopsy, followed by radiation therapy (in all patients) and <a class="drug drug_general" data-topicid="9699" href="/d/drug information/9699.html" rel="external">temozolomide</a> (in later years of the trial) [<a href="#rid41">41</a>]. Although overall survival was similar between groups (9.4 versus 9.0 months), progression-free survival and quality-of-life outcomes favored resection. The trial was limited by slow enrollment, and confidence intervals for survival were wide. We continue to suggest maximal safe resection for most older adults with operable tumors who are good surgical candidates. (See  <a class="medical medical_review" href="/d/html/15246.html" rel="external">"Management of glioblastoma in older adults", section on 'Role of surgery'</a>.)</p><p class="headingAnchor" id="H142081"><span class="h2">BRAF/MEK targeted therapy in papillary craniopharyngioma (July 2023)</span></p><p>Nearly all papillary craniopharyngiomas harbor a <em>BRAF</em> V600E mutation, and new data confirm that these tumors are exquisitely sensitive to combined BRAF/MEK inhibition. In a multicenter, single-arm, phase 2 study in 16 patients with biopsy-confirmed <em>BRAF </em>V600E-mutant papillary craniopharyngioma and no prior therapy, treatment with <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> plus <a class="drug drug_general" data-topicid="105354" href="/d/drug information/105354.html" rel="external">cobimetinib</a> led to a partial or complete response in 15 of 16 patients (94 percent) [<a href="#rid42">42</a>]. Among responders, median volumetric tumor reduction from baseline was 91 percent. For most patients with newly diagnosed <em>BRAF</em>-mutant papillary craniopharyngioma, we suggest a trial of BRAF/MEK inhibition before proceeding with definitive radiation therapy or an attempt at maximal resection; treatment decisions after four to six cycles of therapy should be individualized based on tumor response, patient age, comorbidities, and risks of radiation and surgery. (See  <a class="medical medical_review" href="/d/html/5210.html" rel="external">"Craniopharyngioma", section on 'Targeted therapy for BRAF-mutant tumors'</a>.)</p><p class="headingAnchor" id="H173_142385"><span class="h1">PALLIATIVE AND SUPPORTIVE CARE</span></p><p class="headingAnchor" id="H142385"><span class="h2">Olanzapine for cancer-associated anorexia and cachexia (August 2023)</span></p><p>Studies are evaluating approaches to management of anorexia and cachexia in patients with advanced cancer. In a randomized trial, 124 patients starting chemotherapy for lung, pancreaticobiliary, or stomach cancer were assigned to <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> 2.5 mg daily or placebo [<a href="#rid43">43</a>]. More patients in the olanzapine group experienced at least 5 percent weight gain (60 versus 9 percent) and appetite improvement (43 versus 30 percent). Olanzapine was well tolerated. These and earlier data led the American Society of Clinical Oncology to support low-dose olanzapine once daily to improve weight gain and appetite in patients with advanced cancer [<a href="#rid44">44</a>], while recognizing that the majority of data come from patients with lung or gastrointestinal cancer. (See  <a class="medical medical_review" href="/d/html/2816.html" rel="external">"Management of cancer anorexia/cachexia", section on 'Olanzapine'</a>.)</p><p class="headingAnchor" id="H175_142629"><span class="h1">SOFT TISSUE AND BONE TUMORS</span></p><p class="headingAnchor" id="H142629"><span class="h2">Atezolizumab in alveolar soft parts sarcoma (September 2023)</span></p><p>The prognosis of metastatic alveolar soft parts sarcoma (ASPS) is poor, and trials are investigating immune checkpoint inhibitors as a treatment strategy. In longer follow-up of a previously reported single arm trial in 52 adult and pediatric patients, <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> was associated with a response rate of 37 percent and median progression-free survival of 25 months [<a href="#rid45">45</a>]. There were no grade 4 or 5 events. Atezolizumab is approved by the US Food and Drug Administration for the treatment of adult and pediatric patients with unresectable or metastatic ASPS [<a href="#rid46">46</a>], and we consider it to be an acceptable option for such patients with limited, but progressive, extracranial disease. (See  <a class="medical medical_review" href="/d/html/114329.html" rel="external">"Uncommon sarcoma subtypes", section on 'Limited, progressive disease burden'</a>.)</p><p class="headingAnchor" id="H176_142088"><span class="h1">THORACIC ONCOLOGY</span></p><p class="headingAnchor" id="H143873"><span class="h2">Repotrectinib in advanced ROS1-positive NSCLC (January 2024)</span></p><p>Studies are evaluating novel tyrosine kinase inhibitors (TKIs) in advanced ROS1-positive non-small cell lung cancer (NSCLC). In a study of <a class="drug drug_general" data-topicid="143455" href="/d/drug information/143455.html" rel="external">repotrectinib</a> in 71 patients with such cancers who were naïve to TKIs, the median progression-free survival (PFS) was 36 months and the 18-month overall survival (OS) rate was 88 percent. Among 56 patients with one prior TKI and no chemotherapy, the median PFS was 9 months and OS was 25 months [<a href="#rid47">47</a>]. These data contributed to regulatory approval of repotrectinib in the United States [<a href="#rid48">48</a>]. We consider repotrectinib to be an acceptable initial treatment option for patients with advanced <em>ROS1</em>-positive NSCLC. (See  <a class="medical medical_review" href="/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer", section on 'ROS1 rearrangements'</a>.)</p><p class="headingAnchor" id="H143206"><span class="h2">Tarlatamab in small cell lung cancer (December 2023)</span></p><p>Delta-like ligand 3 is overexpressed in approximately 90 percent of small cell lung cancer (SCLC). In a phase II study in 220 patients with a median of two prior treatments for SCLC, tarlatamab, an investigational bispecific T cell engager immunotherapy directed against delta-like ligand 3, was associated with response rates of 32 percent among those receiving 10 mg daily and 40 percent among those receiving 100 mg daily [<a href="#rid49">49</a>]. Overall survival rates at 9 months were 66 and 68 percent, respectively. The most common adverse events were cytokine-release syndrome (mostly grade 1 to 2), decreased appetite, and pyrexia. Tarlatamab is under regulatory review in the United States and is not yet available outside of a clinical trial. (See  <a class="medical medical_review" href="/d/html/4614.html" rel="external">"Treatment of refractory and relapsed small cell lung cancer", section on 'Other options'</a>.)</p><p class="headingAnchor" id="H143701"><span class="h2">Stereotactic body radiation therapy in oligometastatic NSCLC (December 2023)</span></p><p>For patients with oligometastatic non-small cell lung cancer (NSCLC), studies are evaluating whether local treatment of metastatic lesions, when used in conjunction with standard systemic therapy, can improve outcomes. In an open-label trial including patients with either oligometastatic breast or NSCLC, among the 59 patients with lung cancer, the addition of stereotactic body radiation therapy to standard of care systemic treatment improved median progression-free survival (PFS, 10.0 versus 2.2 months) but failed to improve overall survival (OS) [<a href="#rid50">50</a>]. PFS benefit was not observed among breast cancer patients. For patients with NSCLC and one to three metastases, we suggest using both local therapy and systemic therapy, while recognizing the need for larger studies to clarify the effect on OS. (See  <a class="medical medical_review" href="/d/html/97507.html" rel="external">"Oligometastatic non-small cell lung cancer", section on 'Overall'</a>.)</p><p class="headingAnchor" id="H143586"><span class="h2">Pemetrexed-cisplatin as adjuvant chemotherapy for nonsquamous NSCLC (December 2023)</span></p><p>Although platinum-based doublet chemotherapy is a standard adjuvant regimen for resected non-small cell lung cancer (NSCLC), trials are investigating the optimal chemotherapy agent to pair with the platinum agent. In a randomized trial including 783 patients with stage II to IIIA nonsquamous NSCLC, there was a nonsignificant trend in recurrence-free survival favoring pemetrexed-cisplatin compared with vinorelbine-cisplatin (43 versus 38 months) [<a href="#rid51">51</a>]; overall survival rates were comparable. Previous data suggest lower rates of neutropenia with pemetrexed-based therapy. For those receiving adjuvant chemotherapy for resected nonsquamous histology NSCLC, we suggest <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a> to partner with the platinum agent. (See  <a class="medical medical_review" href="/d/html/4636.html" rel="external">"Systemic therapy in resectable non-small cell lung cancer", section on 'Cisplatin-based doublets'</a>.)</p><p class="headingAnchor" id="H143554"><span class="h2">Osimertinib plus chemotherapy in EGFR-mutant NSCLC (November 2023)</span></p><p>Although the targeted agent <a class="drug drug_general" data-topicid="105441" href="/d/drug information/105441.html" rel="external">osimertinib</a> is standard initial treatment in advanced <em>EGFR-</em>mutated non-small cell lung cancer (NSCLC), trials are evaluating the role of added chemotherapy. In a randomized open-label trial including 557 patients with advanced <em>EGFR</em>-mutated NSCLC, initial treatment with osimertinib plus platinum-pemetrexed chemotherapy improved progression-free survival compared with osimertinib alone (29.4 versus 19.9 month) [<a href="#rid52">52</a>]. At 24 months, overall survival was immature, but there was a nonsignificant trend favoring osimertinib-chemotherapy (hazard ratio 0.9, 95% CI 0.65-1.24). Grade ≥3 adverse events were more common with osimertinib-chemotherapy (64 versus 27 percent). We await longer-term survival data prior to incorporating chemotherapy into the initial treatment strategy for <em>EGFR</em>-mutant NSCLC. (See  <a class="medical medical_review" href="/d/html/4630.html" rel="external">"Systemic therapy for advanced non-small cell lung cancer with an activating mutation in the epidermal growth factor receptor", section on 'Preferred: Osimertinib, with or without chemotherapy'</a>.)</p><p class="headingAnchor" id="H143419"><span class="h2">Pembrolizumab and chemotherapy in advanced pleural mesothelioma (November 2023)</span></p><p>Trials are exploring the role of chemoimmunotherapy in newly diagnosed advanced pleural mesothelioma. In an open-label randomized trial of 440 such patients, the addition of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> (up to two years) to six cycles of platinum- and pemetrexed-based chemotherapy improved median overall survival (17.3 versus 16.1 months) and three-year overall survival (25 and 17 percent) but increased the rate of grade 3 or 4 adverse events (27 versus 15 percent) [<a href="#rid53">53</a>]. Given the modest benefit and added toxicity, we continue to suggest other options in advanced pleural mesothelioma (ipilimumab-nivolumab or chemotherapy alone) but consider pembrolizumab plus chemotherapy to be an acceptable alternative. (See  <a class="medical medical_review" href="/d/html/4609.html" rel="external">"Systemic treatment for unresectable malignant pleural mesothelioma", section on 'Pemetrexed, platinum, and pembrolizumab'</a>.)</p><p class="headingAnchor" id="H143151"><span class="h2">Selpercatinib in RET fusion-positive advanced NSCLC (October 2023)</span></p><p>Trials are investigating novel targeted therapies in oncogene-addicted advanced non-small cell lung cancer (NSCLC). In a randomized trial among 212 patients with advanced <em>RET</em> fusion-positive NSCLC, the RET inhibitor <a class="drug drug_general" data-topicid="128157" href="/d/drug information/128157.html" rel="external">selpercatinib</a> improved median progression-free survival relative to platinum-based chemotherapy (25 versus 11 months) [<a href="#rid54">54</a>]. <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">Pembrolizumab</a> was used with chemotherapy, per investigator's choice. Selpercatinib also improved time to progression in the central nervous system. However, treatment-related grade ≥3 effects were higher with selpercatinib. For patients with advanced <em>RET </em>fusion-positive NSCLC, we suggest selpercatinib rather than chemotherapy or chemoimmunotherapy, but consider <a class="drug drug_general" data-topicid="129470" href="/d/drug information/129470.html" rel="external">pralsetinib</a>, another RET inhibitor, to be a reasonable alternative. (See  <a class="medical medical_review" href="/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer", section on 'RET rearrangements'</a>.)</p><p class="headingAnchor" id="H143183"><span class="h2">Amivantamab plus chemotherapy for advanced NSCLC with EGFR exon 20 insertion (October 2023)</span></p><p>Although established treatment strategies exist for advanced lung cancer with common activating epidermal growth factor receptor (<em>EGFR</em>) mutations, less is known about uncommon activating <em>EGFR</em> mutations, such as exon 20 insertion mutations. In a randomized trial in 308 patients with advanced non-small cell lung cancer (NSCLC) with <em>EGFR</em> exon 20 insertions who had not received previous systemic therapy, those assigned to the targeted agent <a class="drug drug_general" data-topicid="131693" href="/d/drug information/131693.html" rel="external">amivantamab</a> plus chemotherapy experienced a longer progression-free survival relative to those assigned to chemotherapy alone (11.4 versus 6.7 months) [<a href="#rid55">55</a>]. The most common adverse effects in the amivantamab group were reversible hematologic toxicities. For patients with advanced NSCLC with an <em>EGFR</em> exon 20 insertion mutation, we suggest amivantamab plus chemotherapy. (See  <a class="medical medical_review" href="/d/html/4630.html" rel="external">"Systemic therapy for advanced non-small cell lung cancer with an activating mutation in the epidermal growth factor receptor", section on 'For treatment-naïve disease'</a>.)</p><p class="headingAnchor" id="H142904"><span class="h2">Systemic therapy for brain metastases from NSCLC (October 2023)</span></p><p>Trials are evaluating systemic therapy as an initial treatment option for subsets of patients with non-small cell lung cancer (NSCLC) with brain metastases:</p><p class="bulletIndent1"><span class="glyph">●</span>In a single-arm trial of single-agent targeted therapy in 19 patients with KRAS G12C-mutated NSCLC and untreated measurable intracranial disease, <a class="drug drug_general" data-topicid="140357" href="/d/drug information/140357.html" rel="external">adagrasib</a> was associated with an intracranial objective response rate of 42 percent and progression-free survival (PFS) of 5.4 months [<a href="#rid56">56</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a single-arm trial of chemoimmunotherapy in 40 patients with advanced nonsquamous NSCLC with asymptomatic brain metastases, <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> and <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a> was associated with an intracranial median PFS of 6.9 months and response rate of 43 percent [<a href="#rid57">57</a>].</p><p>We consider either of these options to be reasonable initial systemic strategies in the patient populations in the respective trials; nevertheless, radiation is appropriate in such patients with untreated brain metastases, pending further comparative data between radiation and systemic therapy as an initial treatment strategy. (See  <a class="medical medical_review" href="/d/html/114697.html" rel="external">"Brain metastases in non-small cell lung cancer", section on 'KRAS G12C'</a>.)</p><p class="headingAnchor" id="H142932"><span class="h2">Overall survival with adjuvant atezolizumab in resected non-small cell lung cancer (October 2023)</span></p><p>Longer-term overall survival (OS) data are emerging for adjuvant immune checkpoint inhibitors in resected non-small cell lung cancer (NSCLC). In a previously reported randomized trial in 882 patients with stage II to III NSCLC who had undergone surgery and adjuvant cisplatin-based chemotherapy, adjuvant <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> resulted in OS hazard ratios of 0.95 overall, 0.71 among those with programmed death-ligand 1 (PD-L1) tumor cell (TC) ≥1 percent, and 0.43 among those with PD-L1 TC ≥50 percent [<a href="#rid58">58</a>]. OS results remain immature. Based on results from this trial, atezolizumab is approved by the US Food and Drug administration (FDA) as adjuvant treatment following resection and platinum-based chemotherapy for stage II to III NSCLC whose tumors have PD-L1 TC ≥1 percent, as determined by an FDA-approved test [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/d/html/4636.html" rel="external">"Systemic therapy in resectable non-small cell lung cancer", section on 'Adjuvant immunotherapy'</a>.)</p><p class="headingAnchor" id="H141656"><span class="h2">Perioperative checkpoint inhibitors in resectable non-small cell lung cancer (June 2023, Modified October 2023)</span></p><p>Trials are evaluating the role of immune checkpoint inhibitors in resectable non-small cell lung cancer (NSCLC). In a randomized trial in almost 400 patients with resectable stage II to IIIB NSCLC, the addition of neoadjuvant <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> to cisplatin-based chemotherapy, followed by adjuvant pembrolizumab, improved event-free survival rates (62 versus 41 percent at 24 months) and overall survival (median not reached versus 52 months, hazard ratio 0.72) relative to chemotherapy alone [<a href="#rid60">60,61</a>]. In a separate randomized trial in over 800 patients, the addition of perioperative <a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">durvalumab</a> to chemotherapy improved event-free survival rates (63 versus 52 percent at 24 months) [<a href="#rid62">62</a>]. Pembrolizumab has been approval by the US Food and Drug Administration (FDA) in patients with resectable NSCLC ≥4 cm or with node-positive disease, in combination with platinum-based chemotherapy as neoadjuvant treatment, with continuation as a single agent in the adjuvant setting [<a href="#rid63">63</a>]. Perioperative durvalumab does not have FDA approval. (See  <a class="medical medical_review" href="/d/html/4636.html" rel="external">"Systemic therapy in resectable non-small cell lung cancer", section on 'Neoadjuvant/perioperative immunotherapy'</a>.)</p><p class="headingAnchor" id="H142533"><span class="h2">Divarasib in G12C KRAS-mutant solid tumors (September 2023)</span></p><p>Novel agents are under investigation for G12C <em>KRAS</em>-mutant solid tumors. In a phase I study in 137 patients with advanced <em>KRAS</em>-mutant cancers, among the 60 patients with non-small cell lung cancer, the objective response rate to the covalent <em>KRAS </em>G12C inhibitor divarasib was 53 percent, with a median progression-free survival (PFS) of 13.1 months; among the subgroup of 55 patients with metastatic colorectal cancer, the response rate was 29 percent, with a median PFS of 6 months [<a href="#rid20">20</a>]. Responses were also observed in patients with other solid tumors. Treatment was generally well tolerated, with grade ≥3 events occurring in 12 percent of patients. We await further data and/or regulatory approval prior to use of divarasib in G12C <em>KRAS</em>-mutant solid tumors. (See  <a class="medical medical_review" href="/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer", section on 'Others'</a> and  <a class="medical medical_review" href="/d/html/129349.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'RAS-mutated tumors'</a>.)</p><p class="headingAnchor" id="H142582"><span class="h2">Cemiplimab in advanced non-small cell lung cancer (September 2023)</span></p><p>Trials are reporting long-term outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC). In a randomized trial among 565 patients with advanced NSCLC with programmed death-ligand 1 (PD-L1) of ≥50 percent, <a class="drug drug_general" data-topicid="119172" href="/d/drug information/119172.html" rel="external">cemiplimab</a> improved overall survival relative to platinum-doublet chemotherapy at 35 months’ follow-up (26 versus 13 months), with fewer grade 3–4 treatment-emergent adverse events (18 versus 40 percent) [<a href="#rid64">64</a>]. Based on results from this trial, cemiplimab has regulatory approval in the United States for use in patients with advanced NSCLC with PD-L1 of ≥50 percent without an EGFR, ROS1, or ALK genetic aberration [<a href="#rid65">65</a>], and we consider it to be an appropriate option in this setting. (See  <a class="medical medical_review" href="/d/html/90312.html" rel="external">"Initial management of advanced non-small cell lung cancer lacking a driver mutation", section on 'Data regarding checkpoint inhibitor monotherapy'</a>.)</p><p class="headingAnchor" id="H142088"><span class="h2">Nivolumab with stereotactic body radiation therapy in early or locally-recurrent NSCLC (July 2023)</span></p><p>Although stereotactic body radiation therapy (SBRT) is a standard option for nonsurgical candidates with early-stage non small-cell lung cancer (NSCLC), trials are investigating strategies to decrease recurrences. In a randomized trial, 156 patients with stage IA-IIB NSCLC or isolated parenchymal recurrences (tumor size ≤7 cm) were randomly assigned to SBRT with or without four cycles of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> [<a href="#rid66">66</a>]. At a median follow up of 33 months, the nivolumab-SBRT group had better four-year event-free survival than the SBRT only group (77 versus 53 percent). The rate of grade ≥3 events was 15 percent and 0 percent, respectively. While these results are promising, further data are needed prior to incorporation of immunotherapy with SBRT for early or locally-recurrent NSCLC. (See  <a class="medical medical_review" href="/d/html/4642.html" rel="external">"Management of stage I and stage II non-small cell lung cancer", section on 'Stereotactic body radiation therapy'</a>.)</p><p class="headingAnchor" id="H177_142683"><span class="h1">MISCELLANEOUS TUMORS</span></p><p class="headingAnchor" id="H143814"><span class="h2">Maintenance eflornithine in high-risk neuroblastoma (January 2024)</span></p><p>For patients with high-risk neuroblastoma (HRNBL), there is interest in investigating novel maintenance therapies such as eflornithine, an ornithine decarboxylase inhibitor. In an externally controlled analysis of almost 100 patients with HRNBL who completed multimodality treatment and maintenance immunotherapy, extended maintenance therapy with eflornithine was associated with improved overall survival (hazard ratio 0.38) [<a href="#rid67">67</a>]. Based on these data, the US Food and Drug Administration approved eflornithine as maintenance therapy in patients with HRNBL who achieve at least a partial response to prior systemic agents and complete maintenance immunotherapy. Since maintenance eflornithine is not standard across all institutions, this agent may be offered on a case-by-case basis. (See  <a class="medical medical_review" href="/d/html/5203.html" rel="external">"Treatment and prognosis of neuroblastoma", section on 'Eflornithine'</a>.)</p><p class="headingAnchor" id="H142683"><span class="h2">Severe hepatopathy in children with Wilms tumor (November 2023)</span></p><p>For children with Wilms tumor who develop severe hepatopathy (SH) due to chemotherapy and/or radiation therapy, there are limited studies on restarting therapy. In an observational study of almost 9000 patients treated for Wilms tumor with chemotherapy, the incidence of SH was less than 1 percent [<a href="#rid68">68</a>]. Among the 71 patients who developed SH, a majority (85 percent) were able to either continue or restart chemotherapy, typically at reduced doses. These data suggest that most patients with Wilms tumor who develop SH during treatment may be able to safely restart chemotherapy. (See  <a class="medical medical_review" href="/d/html/6237.html" rel="external">"Treatment and prognosis of Wilms tumor", section on 'Late effects'</a>.)</p><p class="headingAnchor" id="H178_141353"><span class="h1">OTHER ONCOLOGY</span></p><p class="headingAnchor" id="H141353"><span class="h2">Updated COVID-19 mRNA vaccine recommendations (September 2023)</span></p><p>The US Food and Drug Administration and Centers for Disease Control and Prevention have updated COVID-19 vaccine authorizations and recommendations [<a href="#rid69">69,70</a>]. Available COVID-19 vaccines have been updated to target Omicron variant XBB.1.5 (<a class="drug drug_general" data-topicid="130318" href="/d/drug information/130318.html" rel="external">Moderna COVID-19 vaccine</a> 2023-2024 formula, Pfizer COVID-19 vaccine 2023-2024 formula, and Novavax 2023-2024 formula); bivalent vaccines are no longer available. An updated 2023-2024 formula vaccine is recommended for all individuals aged six months and older. Immunocompetent individuals five years and older should receive one updated vaccine, regardless of prior vaccination history. For individuals who are four years or younger or have an immunocompromising condition (<a class="graphic graphic_table graphicRef132490" href="/d/graphic/132490.html" rel="external">table 1</a>), the number of recommended updated vaccines depends on their vaccination history. Our approach to COVID-19 vaccination is consistent with these recommendations. (See  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines", section on 'Indications and vaccine selection'</a> and  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines", section on 'Benefits of vaccination'</a>.)</p><p class="headingAnchor" id="H141898"><span class="h2">Direct oral anticoagulants for cancer-related venous thromboembolism (August 2023)</span></p><p>In patients with cancer-related venous thromboembolism (VTE), accumulating evidence suggests that direct oral anticoagulants (DOACs) and subcutaneous low molecular weight heparin (LMWH) have similar efficacy and safety. In a recent randomized trial of over 670 patients with cancer-related VTE, there were no significant differences between rates at six months for recurrent VTE (6.1 [DOACs] versus 8.8 percent [LMWH]) and major bleeding (5.2 [DOACs] versus 5.6 percent [LMWH]) [<a href="#rid71">71</a>]. Despite limitations such as lack of blinding, late randomization, and poor adherence rates with LMWH, these data are in keeping with previous evidence and support our suggestion for DOACs rather than LMWH in patients with cancer-associated VTE. (See  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy", section on 'Direct oral anticoagulant mono- or dual therapy'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Caswell-Jin JL, Sun LP, Munoz D, et al. Analysis of Breast Cancer Mortality in the US-1975 to 2019. JAMA 2024; 331:233.</a></li><li><a class="nounderline abstract_t">Whelan TJ, Smith S, Parpia S, et al. Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer. N Engl J Med 2023; 389:612.</a></li><li><a class="nounderline abstract_t">Mann GB, Skandarajah AR, Zdenkowski N, et al. Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study. Lancet 2023.</a></li><li><a class="nounderline abstract_t">Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials. Lancet 2023; 402:1991.</a></li><li><a class="nounderline abstract_t">Badwe RA, Parmar V, Nair N, et al. Effect of Peritumoral Infiltration of Local Anesthetic Before Surgery on Survival in Early Breast Cancer. J Clin Oncol 2023; 41:3318.</a></li><li><a class="nounderline abstract_t">Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023; 402:1423.</a></li><li class="breakAll">TRODELVY® (sacituzumab govitecan-hziy) for injection, for intravenous use. US Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf (Accessed on February 06, 2023).</li><li><a class="nounderline abstract_t">Moy B, Rumble RB, Carey LA, Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer Expert Panel. Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 2023; 41:1318.</a></li><li><a class="nounderline abstract_t">Dayes IS, Metser U, Hodgson N, et al. Impact of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer. J Clin Oncol 2023; 41:3909.</a></li><li><a class="nounderline abstract_t">Hadoux J, Elisei R, Brose MS, et al. Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. N Engl J Med 2023; 389:1851.</a></li><li class="breakAll">Improvements to MELD, PELD, Status 1A and Status 1B to take effect July 13. United Network for Organ Sharing, 2023. Available at: https://unos.org/news/improvements-to-meld-and-peld-phase-1-data-entry-in-effect-june-15/ (Accessed on September 04, 2023).</li><li><a class="nounderline abstract_t">Marchegiani G, Pollini T, Burelli A, et al. Surveillance for Presumed BD-IPMN of the Pancreas: Stability, Size, and Age Identify Targets for Discontinuation. Gastroenterology 2023; 165:1016.</a></li><li><a class="nounderline abstract_t">Fakih MG, Salvatore L, Esaki T, et al. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. N Engl J Med 2023; 389:2125.</a></li><li><a class="nounderline abstract_t">Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 401:1853.</a></li><li class="breakAll">DailyMed Drug Information: https://dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on January 30, 2024).</li><li><a class="nounderline abstract_t">Nakamura Y, Mizuno N, Sunakawa Y, et al. Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study. J Clin Oncol 2023; 41:5569.</a></li><li><a class="nounderline abstract_t">Dijkstra EA, Nilsson PJ, Hospers GAP, et al. Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial. Ann Surg 2023; 278:e766.</a></li><li><a class="nounderline abstract_t">Zhao L, Zhang X, Coday M, et al. Sugar-Sweetened and Artificially Sweetened Beverages and Risk of Liver Cancer and Chronic Liver Disease Mortality. JAMA 2023; 330:537.</a></li><li><a class="nounderline abstract_t">Bond MJG, Bolhuis K, Loosveld OJL, et al. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group. Lancet Oncol 2023; 24:757.</a></li><li><a class="nounderline abstract_t">Sacher A, LoRusso P, Patel MR, et al. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. N Engl J Med 2023; 389:710.</a></li><li><a class="nounderline abstract_t">Powles TB, Valderrrama BP, Gupta S, et al. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Ann Oncol 2023; 34; S2.</a></li><li><a class="nounderline abstract_t">van der Heijden MS, Sonpavde G, Powles T, et al. Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med 2023; 389:1778.</a></li><li><a class="nounderline abstract_t">Freedland SJ, de Almeida Luz M, De Giorgi U, et al. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med 2023; 389:1453.</a></li><li><a class="nounderline abstract_t">Albiges L, Gurney H, Atduev V, et al. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2023; 24:881.</a></li><li><a class="nounderline abstract_t">Lerner SP, Tangen C, Svatek RS, et al. SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer. J Clin Oncol 2023; 41:16 suppl.</a></li><li><a class="nounderline abstract_t">Albiges L, Rini BI, Peltola K, De Velasco Oria. https://www.annalsofoncology.org/article/S0923-7534(23)04234-5/fulltext. Ann Oncol 2023; 34;2S.</a></li><li><a class="nounderline abstract_t">Oaknin A, Gladieff L, Martínez-García J, et al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet 2024; 403:31.</a></li><li><a class="nounderline abstract_t">Moore KN, Angelergues A, Konecny GE, et al. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med 2023; 389:2162.</a></li><li class="breakAll">Medication guide for Lynparza olaparib tablets. US Food and Drug Administration, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s029lbl.pdf (Accessed on September 25, 2023).</li><li class="breakAll">Dear Health Care Provider Letter (Niraparib). GSK. December 2022. Available at: https://www.zejulahcp.com/content/dam/cf-pharma/hcp-zejulahcp-v2/en_US/pdf/Zejula-(niraparib)DearHCPLetterDec2022.pdf (Accessed on December 16, 2022).</li><li class="breakAll">RUBRACA® (rucaparib) tablets, for oral use. U.S. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf (Accessed on January 04, 2023).</li><li><a class="nounderline abstract_t">Nutting C, Finneran L, Roe J, et al. Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial. Lancet Oncol 2023; 24:868.</a></li><li><a class="nounderline abstract_t">Lou PJ, Jacky Lam WK, Hsu WL, et al. Performance and Operational Feasibility of Epstein-Barr Virus-Based Screening for Detection of Nasopharyngeal Carcinoma: Direct Comparison of Two Alternative Approaches. J Clin Oncol 2023; 41:4257.</a></li><li><a class="nounderline abstract_t">Li T, Li F, Guo X, et al. Anti-Epstein-Barr Virus BNLF2b for Mass Screening for Nasopharyngeal Cancer. N Engl J Med 2023; 389:808.</a></li><li><a class="nounderline abstract_t">Nathan P, Hassel JC, Rutkowski P, et al. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med 2021; 385:1196.</a></li><li><a class="nounderline abstract_t">Hassel JC, Piperno-Neumann S, Rutkowski P, et al. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med 2023; 389:2256.</a></li><li><a class="nounderline abstract_t">Becker JC, Ugurel S, Leiter U, et al. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial. Lancet 2023; 402:798.</a></li><li><a class="nounderline abstract_t">Roder C, Stummer W, Coburger J, et al. Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial. J Clin Oncol 2023; 41:5512.</a></li><li><a class="nounderline abstract_t">Bouffet E, Hansford JR, Garrè ML, et al. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. N Engl J Med 2023; 389:1108.</a></li><li><a class="nounderline abstract_t">Benusiglio PR, Elder F, Touat M, et al. Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma. JCO Precis Oncol 2023; 7:e2200525.</a></li><li><a class="nounderline abstract_t">Laigle-Donadey F, Metellus P, Guyotat J, et al. Surgery for glioblastomas in the elderly: an Association des Neuro-oncologues d'Expression Française (ANOCEF) trial. J Neurosurg 2023; 138:1199.</a></li><li><a class="nounderline abstract_t">Brastianos PK, Twohy E, Geyer S, et al. BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas. N Engl J Med 2023; 389:118.</a></li><li><a class="nounderline abstract_t">Sandhya L, Devi Sreenivasan N, Goenka L, et al. Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer. J Clin Oncol 2023; 41:2617.</a></li><li><a class="nounderline abstract_t">Roeland EJ, Bohlke K, Baracos VE, et al. Cancer Cachexia: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 2023; 41:4178.</a></li><li><a class="nounderline abstract_t">Chen AP, Sharon E, O'Sullivan-Coyne G, et al. Atezolizumab for Advanced Alveolar Soft Part Sarcoma. N Engl J Med 2023; 389:911.</a></li><li class="breakAll">Atezolizumab: United States Food and Drug Administration Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf (Accessed on December 14, 2022).</li><li><a class="nounderline abstract_t">Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2024; 390:118.</a></li><li class="breakAll">AUGTYRO (repotrectinib) capsules, for oral use. US Prescribing Information. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218213s000lbl.pdf (Accessed on November 17, 2023).</li><li><a class="nounderline abstract_t">Ahn MJ, Cho BC, Felip E, et al. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. N Engl J Med 2023; 389:2063.</a></li><li><a class="nounderline abstract_t">Tsai CJ, Yang JT, Shaverdian N, et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet 2024; 403:171.</a></li><li><a class="nounderline abstract_t">Kenmotsu H, Yamamoto N, Misumi T, et al. Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2023; 41:5242.</a></li><li><a class="nounderline abstract_t">Planchard D, Jänne PA, Cheng Y, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med 2023; 389:1935.</a></li><li><a class="nounderline abstract_t">Chu Q, Perrone F, Greillier L, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet 2023; 402:2295.</a></li><li><a class="nounderline abstract_t">Zhou C, Solomon B, Loong HH, et al. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. N Engl J Med 2023; 389:1839.</a></li><li><a class="nounderline abstract_t">Zhou C, Tang KJ, Cho BC, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med 2023; 389:2039.</a></li><li><a class="nounderline abstract_t">Negrao MV, Spira AI, Heist RS, et al. Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases. J Clin Oncol 2023; 41:4472.</a></li><li><a class="nounderline abstract_t">Nadal E, Rodríguez-Abreu D, Simó M, et al. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05). J Clin Oncol 2023; 41:4478.</a></li><li><a class="nounderline abstract_t">Felip E, Altorki N, Zhou C, et al. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Ann Oncol 2023; 34:907.</a></li><li class="breakAll">Atezolizumab injection. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761034Orig1s042lbl.pdf (Accessed on October 27, 2021).</li><li><a class="nounderline abstract_t">Wakelee H, Liberman M, Kato T, et al. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J Med 2023; 389:491.</a></li><li><a class="nounderline abstract_t">Spicer JD, Gao S, Liberman M, et al. Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). Ann Oncol 2023; 34S:S1297.</a></li><li><a class="nounderline abstract_t">Heymach JV, Harpole D, Mitsudomi T, et al. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N Engl J Med 2023; 389:1672.</a></li><li class="breakAll">KEYTRUDA (pembrolizumab) injection, for intravenous use. US Prescribing Information. US Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s139lbl.pdf (Accessed on October 18, 2023).</li><li><a class="nounderline abstract_t">Özgüroğlu M, Kilickap S, Sezer A, et al. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2023; 24:989.</a></li><li class="breakAll">Cemiplimab-rwlc injection. United States Prescribing Information. US National Library of Medicine. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761097s000lbl.pdf (Accessed on February 26, 2021).</li><li><a class="nounderline abstract_t">Chang JY, Lin SH, Dong W, et al. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet 2023; 402:871.</a></li><li><a class="nounderline abstract_t">Oesterheld J, Ferguson W, Kraveka JM, et al. Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons. J Clin Oncol 2024; 42:90.</a></li><li><a class="nounderline abstract_t">Oosterom N, Gooskens SLM, Renfro LA, et al. Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes After Reintroduction of Chemotherapy. J Clin Oncol 2023; 41:4247.</a></li><li class="breakAll">Recommendation for the 2023-2024 Formula of COVID-19 vaccines in the US. https://www.fda.gov/media/169591/download?attachment (Accessed on September 11, 2023).</li><li class="breakAll">Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html (Accessed on April 26, 2023).</li><li><a class="nounderline abstract_t">Schrag D, Uno H, Rosovsky R, et al. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial. JAMA 2023; 329:1924.</a></li></ol></div><div id="topicVersionRevision">Topic 8361 Version 12473.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38227031" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Analysis of Breast Cancer Mortality in the US-1975 to 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37585627" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38065194" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37931633" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37023374" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effect of Peritumoral Infiltration of Local Anesthetic Before Surgery on Survival in Early Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37633306" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37633306" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36626701" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37235845" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Impact of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37870969" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37870969" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37406887" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Surveillance for Presumed BD-IPMN of the Pancreas: Stability, Size, and Age Identify Targets for Discontinuation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37870968" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37075781" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37075781" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37751561" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36661037" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37552302" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Sugar-Sweetened and Artificially Sweetened Beverages and Risk of Liver Cancer and Chronic Liver Disease Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37329889" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37611121" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37870949" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37851874" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37451291" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : https://www.annalsofoncology.org/article/S0923-7534(23)04234-5/fulltext</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38048793" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38055253" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38055253" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38055253" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38055253" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37423227" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37478397" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Performance and Operational Feasibility of Epstein-Barr Virus-Based Screening for Detection of Nasopharyngeal Carcinoma: Direct Comparison of Two Alternative Approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37646678" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Anti-Epstein-Barr Virus BNLF2b for Mass Screening for Nasopharyngeal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34551229" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37870955" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37451295" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37335962" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37733309" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37262394" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36242578" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Surgery for glioblastomas in the elderly: an Association des Neuro-oncologues d'Expression Française (ANOCEF) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37437144" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36977285" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37467399" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cancer Cachexia: ASCO Guideline Rapid Recommendation Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37672694" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Atezolizumab for Advanced Alveolar Soft Part Sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37672694" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Atezolizumab for Advanced Alveolar Soft Part Sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38197815" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38197815" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37861218" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38104577" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37656928" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37937763" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37931632" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37870973" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37870976" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37327468" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37603816" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37467930" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37467930" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37272513" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37870974" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37870974" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37591293" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37591293" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37478883" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37883734" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37343199" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes After Reintroduction of Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37343199" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes After Reintroduction of Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37343199" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes After Reintroduction of Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37266947" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
